MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Study ID
NCT07409454
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • anti-BCMA/CD3 bispecific antibody — DRUG
    Anti-BCMA/CD3 bispecific antibody (CM336) will be administered via a subcutaneous injection (SC).

Study Details

This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Key Dates

First listed
Feb 13, 2026
Start date
Mar 1, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BsAbs-treatment group

Primary Outcome Measure

Minimal residual disease (MRD) negativity conversion rate [ Time Frame: Up to 24 months ]

Central Contacts

Find similar trials

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials

Related Studies